Guasti L, et al. – The clinicians evaluated the effects of canrenone addition on ambulatory blood pressure (BP) in uncontrolled hypertensive patients already treated with the highest tolerated dose of angiotensin–converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor (AT1R) antagonists plus hydrochlorothiazide (HCT). In patients with uncontrolled stage 1 or 2 hypertension, canrenone addition to ACE inhibitors or AT1R antagonists plus HCT offered a significant reduction of 24 h BP. Moreover, an increased number of patients also achieved 24 h ambulatory blood pressure monitoring (ABPM) targets.